2.5 Mesenchymal Stem Cell Therapy has significant clinical effect in proteoglycan induced arthritis
© Swart et al; licensee BioMed Central Ltd. 2008
Published: 15 September 2008
We performed a study with 104 Balb/c mice with 55 as donors of MSC. The 49 mice that were induced twice with human proteoglycan for the development of PGIA were randomly assigned to 5 groups: 1 control-group (PBS) and 4 treatment-groups (MSC once or twice intraperitoneal [ip] or intra-articular [ia]). Ten days after 2nd PG-antigen injection, treatment was started and if planned again after 4 weeks. Dosages were 5 × 106 ip and 1 × 106 cells ia. MSC used were syngeneic and passaged twice. Arthritis was scored 2 times a week by 2 independent observers according to a scoringsystem with a maximum of 16.
Arthritis-score was on average 1.3 (0.8–2.0) just before start of the treatment and increased to 6.0 in the control group towards the end of the experiment (day 67). At day 67 arthritis-scores were significantly lower in both ip-groups (1.0 and 0.5) and in the repeated ia-group (2.0). Furthermore in both ip-groups arthritis-scores decreased after treatment and stabilized until day 67.
High dose MSC systemically administered (ip) has good clinical effect on established arthritis. Arthritisscore not only stabilized but even diminished after injection of ip MSC. Ip injection of MSC once was as good as twice; this was not true for the ia injection.